CANBERA (dpa-AFX) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO.
The collaboration is intended to increase physician awareness of PSMA-informed treatment pathways, support appropriate patient selection and treatment planning, and expand access to the TULSA Procedure.
'Over time, we also believe the incorporation of Telix's PSMA-PET capabilities within TULSA-PRO centers could strengthen their clinical and economic value proposition, including by supporting more informed treatment decisions and potentially enhancing return on investment,' said Profound CEO Arun Menawat.
In pre-market hours, PROF was trading at $6.81, down 1.51 percent, and TLX closed trading at $11.01, down 0.99 percent on the Nasdaq.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
